EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited

View source ↗

Summary

EMA authorised Taltz (ixekizumab) for multiple indications including psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis in Juvenile Patients
• Axial Spondyloarthritis
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• TALTZ (IXEKIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Axial Spondyloarthritis;Arthritis, Juvenile. MAH: Eli Lilly and Company (Ireland) Limited. Decision date: 26/03/2026